查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1190729

Elispot 和 Fluorospot 检测市场 - COVID-19 的增长、趋势、影响和预测 (2023-2028)

Elispot and Fluorospot Assay Market - Growth, Trends, and Forecasts (2023 - 2028)
出版日期: | 出版商: Mordor Intelligence | 英文 111 Pages | 商品交期: 2-3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

在预测期内（2022 年至 2027 年），Elispot 和 Fluorospot 检测市场预计将以超过 13.3% 的全球复合年增长率增长。

COVID-19 大流行影响了全球医疗保健系统，也对 Elispot 和 Fluorospot 检测市场产生了重大影响。 根据 2020 年发表的一篇 Medtech 文章，COVID-19 中的抗体滴度和 T 细胞反应性之间似乎存在联繫。 在抗体滴度最低的三名 COVID-19 患者（C4、C5、C7）的 FluoroSpot 检测中，观察到最多数量的 IFN-/IL-2 分泌细胞和最强的 T 细胞反应。 因此，Elispot 和 Fluorospot 已被用于 COVID-19 患者，以确认 SARS-CoV-2 特异性 T 细胞和 B 细胞免疫力。

推动 Elispot 和 Fluorospot 检测市场增长的关键因素是疫苗研究的兴起以应对耐药菌株的挑战、全球慢性病发病率的增加、推动 Elispot 和 Fluorospot 检测市场的增长。ELISpot 的创新和 FluoroSpot 分析仪和检测试剂盒。 根据 Globocan 2020 Fact Sheet，全球估计有 19,292,789 例新诊断的癌症病例和大约 9,958,133 例癌症死亡病例。 此外，国际癌症研究机构 (IARC) 估计，到 2040 年，全球癌症负担预计将导致 2750 万新癌症病例和 1630 万死亡病例增加。 由于癌症患者的增加，预计 Elispot 和 Flurospot 检测的市场需求将会增加。 根据世界卫生组织 (WHO) 2021 年 4 月更新，非传染性疾病 (NCD) 每年导致 4100 万人死亡（占全球所有死亡人数的 71%），超过 1500 万人死于 69 至 69 岁之间的非传染性疾病，而这些“过早”死亡中有 85% 发生在低收入和中等收入国家。 因此，增加慢性病的患病率以促进市场研究。

ELISpot 是许多疾病疫苗开发的重要途径：艾滋病、结核病、艾滋病毒、疟疾、癌症、流感等。 ELISpot 测试是临床试验中用于评估疫苗的最广泛使用的免疫测定之一。 该评估主要基于样本敏感性、统计可读性以及在大规模筛选和个体研究中的易用性。 该测试可用于评估 T 细胞反应和产生疫苗特异性抗体的 B 细胞。

因此，考虑到上述因素，预计癌症治疗市场在预测期内将出现巨大增长。

Elispot 和 Fluorospot 分析市场趋势

Elispot 和 Fluorospot 检测市场，检测试剂盒有望占据最大市场份额

检测试剂盒广泛应用于生命科学研究、药物开发和环境监测，包括疾病途径调查、有希望的候选药物筛选以及生物製药生产过程评估。

由于慢性病发病率高以及临床试验中越来越多地使用疫苗开发产品等因素，检测试剂盒占据了市场主导地位。

根据世界卫生组织 (WHO) 2020 年 12 月的数据，目前主要慢性病占全球死亡人数的 60% 左右，占疾病负担的 43% 左右。 到 2020 年，预计死亡人数将增加到 73%，发病率将增加到 60%。 在新兴市场，79% 的死亡是由于慢性病。 此外，ELISpot 和 FluoroSpot 检测试剂盒和分析仪的技术创新也有望推动市场增长。

北美主导市场，预计在预测期内也会如此

在整个预测期内，预计北美将主导整个 Elispot 和 Fluorospot 检测市场。 这是由于诸如传染病等慢性病患病率上升和老年人口不断增加等因素造成的。

根据 Globocan 2020 报告，估计 2020 年美国将诊断出 2,281,658 例新癌症病例。 2020 年美国最常见的癌症是乳腺癌 (253,465)、肺癌 (227,875)、前列腺癌 (209,512) 和结肠癌 (101,809)。 与其他发达国家相比，美国是某些慢性病（如癌症和心血管疾病）患病率最高的国家之一，这将对该国研究市场的增长产生重大影响。存在这种可能性。

此外，根据美国疾病控制与预防中心 2021 年的数据，在美国，心脏病、癌症和糖尿病等慢性病是导致死亡和残疾的主要原因。 他们也是美国每年 3.8 万亿美元医疗保健支出的主要驱动力。 因此，慢性病患病率上升和医疗成本上升将是预测期内推动该国市场的因素。

Elispot 和 Fluorospot 检测市场的竞争分析

Elispot 和 Fluorospot 检测市场竞争激烈，由几家大型企业组成。 就市场份额而言，目前几家主要参与者主导着市场。 一些知名企业正在积极收购其他公司或推出新产品，以巩固其在全球的市场地位。

其他好处

  • Excel 格式的市场预测 (ME) 表
  • 三个月的分析师支持

内容

第一章介绍

  • 研究假设和市场定义
  • 调查范围

第二章研究方法论

第 3 章执行摘要

第四章市场动态

  • 市场概览
  • 市场驱动因素
    • 慢性病发病率增加
    • ELISpot 和 FluoroSpot 检测试剂盒及分析仪的技术突破
  • 市场製约因素
    • 替代检测技术的可用性
  • 波特的五力分析
    • 新进入者的威胁
    • 买方/消费者议价能力
    • 供应商的议价能力
    • 替代品的威胁
    • 竞争公司之间的敌对关係

第 5 章市场细分（基于价值的市场规模：百万美元）

  • 按产品分类
    • 分析仪
    • 检测试剂盒
    • 辅助产品
  • 最终用户
    • 医院和研究机构
    • 生物製药公司
    • 研究所
  • 通过申请
    • 调查
      • 疫苗开发
      • 临床试验
      • 癌症研究
    • 诊断
      • 感染
      • 移植
  • 按地区
    • 北美
      • 美国
      • 加拿大
      • 墨西哥
    • 欧洲
      • 德国
      • 英国
      • 法国
      • 意大利
      • 西班牙
      • 其他欧洲地区
    • 亚太地区
      • 中国
      • 日本
      • 印度
      • 澳大利亚
      • 韩国
      • 其他亚太地区
    • 中东和非洲
      • 海湾合作委员会
      • 南非
      • 其他中东和非洲地区
    • 南美洲地区
      • 巴西
      • 阿根廷
      • 其他南美洲

第六章竞争格局

  • 公司简介
    • Becton, Dickinson and Company
    • U-Cytech Biosciences
    • Cellular Technologies Limited
    • Mabtech AB
    • Abcam
    • Autoimmun Diagnostika GmbH
    • Lophius Biosciences GmbH
    • Bio-Connect B.V.
    • Oxford Immunotec
    • Bio-Techne Corporation

第7章 市场机会今后动向

简介目录
Product Code: 67517

The ELISpot and FluoroSpot Assay Market is expected to grow at a CAGR of more than 13.3%*globally during the forecast period (2022-2027).

The COVID-19 pandemic has affected the healthcare systems globally and also has had a significant impact on the ELISpot and FluoroSpot assay market. According to the article by Medtech published in 2020, there seems to be a link between antibody titers and T-cell responsiveness in COVID-19. The strongest T cell response was observed as the highest number of IFN-/IL-2 secreting cells in a FluoroSpot assay in three individuals (C4, C5, and C7) with the lowest antibody response in COVID-19 patients. Thus, to check the SARS-CoV-2-specific T- and B-cell immunity, the elispot and flurospot are used in COVID-19 patients.

The major factors attributing to the growth of the ELISpot and FluoroSpot assay market are the rising vaccine research to tackle the drug-resistant strains challenge, the growing global occurrence of chronic illnesses, and technological innovations in ELISpot and FluoroSpot analyzers and assay kits which are assessed to upsurge the market growth for ELISpot and FluoroSpot assay. According to the Globocan 2020 fact sheet, an estimated 19,292,789 new cancer cases were diagnosed worldwide, with nearly 9,958,133 deaths due to cancers globally. Additionally, according to estimates from the International Agency for Research on Cancer (IARC), by 2040, the global burden of cancers is expected to grow to 27.5 million new cancer cases and 16.3 million deaths worldwide. The increasing incidence of cancer cases is expected to drive the need for elispot and flurospot assay markets. In addition, according to an April 2021 update by the World Health Organization (WHO), non-communicable diseases (NCDs) kill 41 million people each year, equivalent to 71% of all deaths globally, and each year, more than 15 million people die from an NCD between the ages of 30 and 69 years; 85% of these "premature" deaths occur in low- and middle-income countries. Thus increasing the prevalence of chronic diseases to boost the market study.

ELISpot is a crucial path to vaccine development for many illnesses, namely AIDS, tuberculosis, HIV, malaria, cancer, and flu. The ELISpot test is among the most widely utilized immunoassays in clinical studies to assess vaccines. This reputation was based mainly on the higher sensitivity of the sample, statistical read-out, and ease of use in both large screening and individual tests. The test can be used to assess both T-cell reactions and vaccine-specific antibody-producing B cells.

Thus, given the aforementioned factors, the cancer therapy market is expected to witness tremendous growth over the forecast period.

ELISpot and FluoroSpot Assay Market Trends

Assay Kits is Expected to Hold the Largest Market Share in the ELISpot and FluoroSpot Assay Market

Assay kits are employed in a wide range of applications in life science research, drug development, and environmental monitoring, including researching disease pathways, screening for prospective drug candidates, and evaluating biopharmaceutical production processes.

Dominant share is retained by the assay kits segment owing to the factors such as a high incidence of chronic ailments and increased use of these products for vaccine development in clinical studies.

As per the (WHO) World Health Organization December 2020, the main chronic illnesses presently make up nearly 60% of all fatalities and 43% of the worldwide disease burden. Their contribution is projected to increase up to 73% of all fatalities by 2020 and 60% of the worldwide morbidity. In addition, in developing countries, 79% of the deaths take place owing to chronic diseases. Furthermore, the technological innovation of assay kits and analyzers for ELISpot and FluoroSpot is also expected to drive market growth.

North America Dominates the Market and Expected to do Same in the Forecast Period

North America is expected to dominate the overall ELISpot and FluoroSpot assay market throughout the forecast period. This is owing to factors such as the rising prevalence of chronic disorders such as infectious diseases and the geriatric population.

According to the Globocan 2020 report, an estimated 2,281,658 new cancer cases will be diagnosed in United States in 2020. In 2020, The most common cancers were breast (253,465), lung (227,875), prostate (209,512), and colon (101,809) in United States. United States has one of the highest prevalences of some chronic diseases, such as cancer and cardiovascular diseases, as compared to other developed countries, which may have a significant impact on the growth of the studied market in the country.​

Furthermore, according to the Center for Disease Control and Prevention 2021, in United States, chronic diseases such as heart disease, cancer, and diabetes are the main causes of mortality and disability. They are also the main drivers of the USD3.8 trillion in annual healthcare spending in United States. Thus rising prevalence of chronic diseases and growing healthcare spending boost the market in the country over the forecast period.

ELISpot and FluoroSpot Assay Market Competitive Analysis

The ELISpot and FluoroSpot assay market is moderately competitive and consists of a few major players. In terms of market share, few of the major players are currently dominating the market. And some prominent players are vigorously making acquisitions and new product launches with the other companies to consolidate their market positions across the globe.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Incidence of Chronic Diseases
    • 4.2.2 Technological Breakthroughs in Test Kits and analyzers for ELISpot and FluoroSpot
  • 4.3 Market Restraints
    • 4.3.1 Availability of alternative detection technologies
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD million)

  • 5.1 By Product
    • 5.1.1 Analyzers
    • 5.1.2 Assay kits
    • 5.1.3 Ancillary Products
  • 5.2 By End User
    • 5.2.1 Hospitals & Clinical labs
    • 5.2.2 Biopharmaceutical Company
    • 5.2.3 Research Institutes
  • 5.3 By Application
    • 5.3.1 Research
      • 5.3.1.1 Vaccine Development
      • 5.3.1.2 Clinical Trials
      • 5.3.1.3 Cancer Research
    • 5.3.2 Diagnostics
      • 5.3.2.1 Infectious Disease
      • 5.3.2.2 Transplants
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 United States
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 United Kingdom
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle-East and Africa
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle-East and Africa
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Becton, Dickinson and Company
    • 6.1.2 U-Cytech Biosciences
    • 6.1.3 Cellular Technologies Limited
    • 6.1.4 Mabtech AB
    • 6.1.5 Abcam
    • 6.1.6 Autoimmun Diagnostika GmbH
    • 6.1.7 Lophius Biosciences GmbH
    • 6.1.8 Bio-Connect B.V.
    • 6.1.9 Oxford Immunotec
    • 6.1.10 Bio-Techne Corporation

7 MARKET OPPORTUNITIES AND FUTURE TRENDS